Bristol Myers acquires cell therapy partner 2seventy bio
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...
This was the stock's second consecutive day of losses.
1d
Zacks.com on MSNBristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key FactsBristol Myers Squibb (BMY) closed at $60.28 in the latest trading session, marking a +0.79% move from the prior day.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results